ECKUITY CAPITAL
Insights & Research

Perspectives on
healthcare & capital.

Original research, market perspectives, and news from our investment team and portfolio companies.

Featured
Research Note

Private Capital has a Misallocation Problem

An analysis of structural capital misallocation in private markets and the opportunity it creates for disciplined, sector-focused investors deploying operational infrastructure alongside capital.

February 2026Research Note Q1 2026
Download
White Papers
4 publications
Investor Perspective

An Investor's Perspective: The Impact of AI in Healthcare

Examining the transformative potential of artificial intelligence across healthcare delivery, diagnostics, and operational efficiency from the lens of a growth equity investor.

October 2025Commentary
Commentary

Everything Is Peanut Butter

A commentary on the dangers of undifferentiated capital allocation and the case for concentrated, conviction-driven investment strategies in healthcare.

December 2024Commentary
Commentary

The One-Handed Economist

A reflection on the value of conviction and decisiveness in healthcare investing, and why the best investors avoid the temptation of equivocation.

August 2023Commentary
News & Updates
PE Hub

Eckuity Capital's Youssef Sebban Bets on Healthcare in Home Setting; Partners Group Sells Logistics Biz

PE Hub profiles Eckuity Capital's investment thesis and Youssef Sebban's conviction in healthcare-at-home as a transformative sector.

2026
DI Cardiology

Kardium Publishes Positive Trial Results for Globe Pulsed Field System

The PULSAR trial demonstrates strong efficacy and safety data for Kardium's Globe Pulsed Field System in treating paroxysmal atrial fibrillation.

Jan 2026
Kardium
FluidAI Medical

FluidAI Medical Announces Acquisition of Emmetros Limited

The acquisition enhances Stream Inara, an AI-powered patient education and engagement platform within FluidAI's product portfolio.

Nov 2025
FluidAI
Endeavor BioMedicines

Endeavor BioMedicines Receives PRIME Designation from EMA for Taladegib

Taladegib (ENV-101) receives Priority Medicines designation from the European Medicines Agency for the treatment of idiopathic pulmonary fibrosis.

Nov 2025
Endeavor
Samsara Vision

Samsara Vision Launches PERSPECTIVE Clinical Trial for Next-Gen IMT

First pseudophakic surgery completed in the PERSPECTIVE trial evaluating the Smaller-Incision New-Generation Implantable Miniature Telescope.

Oct 2025
Samsara Vision
PR Newswire

Avive Connect AED Approved for Use on Aircraft

The Avive Connect AED, the market's smallest AED, receives approval for in-flight use, enabling immediate access to critical post-use data.

Sep 2025
Avive
PR Newswire

FluidAI Medical's Origin Device Receives FDA 510(k) Clearance

Origin, a real-time postoperative bedside monitoring device, achieves FDA clearance, redefining the future of data-driven post-operative care.

Sep 2025
FluidAI
MedTech Dive

Kardium Receives FDA Approval for Globe Pulsed Field Ablation System

Kardium receives premarket approval for its Globe pulsed field ablation system, the only integrated high-density cardiac mapping and ablation platform.

Sep 2025
Kardium
Eckuity Capital

Eckuity Capital Invests in Kardium Inc

Eckuity Capital invests in Kardium Inc, the developer of the Globe Pulsed Field System, an innovative treatment for atrial fibrillation.

Jul 2025
Digital Health

Huma Partners with Eckuity Capital and Acquires Aluna

Global healthcare AI firm Huma Therapeutics partners with Eckuity Capital and acquires remote monitoring company Aluna.

May 2025
Huma
DDW Online

Sonrai Analytics Partners with Paige to Improve AI Drug Discovery

Sonrai Analytics and Paige form a strategic partnership to combine AI-driven multi-modal data management with proprietary foundation models.

Apr 2025
Sonrai
Caresyntax

Caresyntax Raises $180 Million to Accelerate Precision Surgery

Caresyntax raises $180 million through a Series C extension and growth debt expansion to accelerate adoption of its surgical intelligence platform.

Aug 2024
Caresyntax

Stay informed.

Receive our quarterly market perspectives and sector analysis directly. Reserved for institutional investors and healthcare operators.